ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

ACC.23 In the COORDINATE-Diabetes trial was investigated whether a multifaceted intervention can improve prescription of 3 groups of evidence-based therapies in patients with T2DM and ASCVD.

ACC.23 Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

ACC.23 UK Biobank participants who followed a low-carbohydrate high-fat diet had higher LDL-c and apoB levels and an increased risk of incident MACE compared with those on a standard diet.

ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.